New study pits two biologics against tough Crohn's complication
NCT ID NCT07444060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two drugs, guselkumab and ustekinumab, in 100 adults with moderate-to-severe Crohn's disease that has caused narrowing (strictures) in the bowel. The goal is to see which drug better controls symptoms and improves imaging results over 52 weeks. Participants continue their usual care, and the study tracks how well the drugs work without the need for additional treatments or surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD - CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sleep hormone melatonin put to the test for IBD patients with poor sleep
- Which diet do IBD patients prefer? intermittent fasting, mediterranean, or low FODMAP?
- Could a postbiotic soothe irritable bowel syndrome?
- Podcast vs. pamphlet: which boosts IBD knowledge best?
- New oral drug for inflammatory bowel disease enters first human tests
- Double-Drug attack on stubborn IBD shows promise